CureVac Begins Human Trials of Optimized mRNA COVID-19 Vaccine

CureVac AG (Tübingen, Germany) has received regulatory approval from the German and Belgian authorities to initiate Phase 1 clinical trial of its SARS-CoV-2 vaccine candidate. CureVac, a clinical-stage biopharmaceutical company developing a new class of transformative medicines based on optimized mRNA, has received approval from the German Health Authority Paul-Ehrlich-Institute (PEI) and the Belgian Federal Agency for Medicines and Health Products (FAMHP) to begin the Phase 1 clinical trial for its vaccine program to prevent SARS-CoV-2 infection. The trial will be conducted in Germany and Belgium.